Lung Cancer

Checkpoint blockade immunotherapy has been hailed as a significant advance in anticancer treatment. Yet only a subset of patients experience long-term cancer remission as a result of these therapies, because a significant number of those who initially respond eventually develop resistance.

Kathryn Mileham, MD, medical oncologist, Levine Cancer Institute, Carolinas HealthCare System, discusses biomarkers in lung cancer.

Treatment with the combination of atezolizumab, bevacizumab, carboplatin, and paclitaxel delayed progression or death by 38% compared with bevacizumab and chemotherapy alone for patients with advanced non-squamous non–small cell lung cancer.

Vincent K. Lam, MD, discusses the treatment paradigm for patients with ALK/ROS1-translocated NSCLC.

George R. Simon, MD, discusses the advancements being made with immunotherapy for the treatment of NSCLC.

Frank E. Mott, MD, discusses optimal treatment selection strategies for patients with NSCLC.

Nivolumab improved survival versus docetaxel in a predominantly Chinese population of patients with pretreated advanced or metastatic non-small cell lung cancer.

Edward S. Kim, MD, chair, Solid Tumor Oncology and Investigational Therapeutics, Donald S. Kim Distinguished Chair for Cancer Research, Levine Cancer Institute, Carolinas HealthCare System, discusses the importance of biomarker testing in lung cancer.

Justin F. Gainor, MD, assistant professor of medicine, Harvard Medical School, attending physician, Massachusetts General Hospital, discusses the future of treatment for patients with EGFR-positive non-small cell lung cancer.

A sNDA has been submitted to Japan’s Pharmaceuticals and Medical Devices Agency for the use of osimertinib (Tagrisso) as a frontline treatment for patients with inoperable or recurrent EGFR-positive NSCLC.

George R. Blumenschein, MD, discusses the current treatment landscape for patients with squamous cell lung cancer.

Josh H. Heinzerling, MD, Department of Radiation Oncology, Levine Cancer Institute, discusses the development of new treatment regimens for patients with early-stage lung cancer.

The FDA granted a priority review to durvalumab in October for the treatment of patients with stage III, unresectable non-small cell lung cancer whose disease has not progressed following platinum-based chemoradiation.

Raghava R. Induru, MD, medical oncologist, Levine Cancer Institute, discusses other mutations in lung cancer.

New results again demonstrated the benefit of frontline osimertinib in patients with EGFR-positive advanced non-small cell lung cancer and CNS metastases at baseline.

The addition of atezolizumab to bevacizumab, carboplatin, and paclitaxel delayed progression or death compared with bevacizumab and chemotherapy alone for patients with advanced non-squamous non–small cell lung cancer.

Jared Weiss, MD, assistant professor, UNC Lineberger Comprehensive Cancer Center, discusses how and when to biopsy patients for lung cancer.

Josh H. Heinzerling, MD, Department of Radiation Oncology, Levine Cancer Institute, discusses remaining challenges for treating stage III non–small cell lung cancer (NSCLC).

Frances A. Shepherd, MD, has spent more than 3 decades demonstrating that medical oncology can help patients with lung cancer during all stages of their journey.

Frank E. Mott, MD, associate professor, Department of Thoracic/Head and Neck Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the sequencing of treatments for patients with non-small cell lung cancer (NSCLC).

Suresh A. Ramalingam, MD, discusses some of the changes to the NCCN guidelines in non-small cell lung cancer, specifically with EGFR-mutation–positive disease, and how the frontline recommendation of osimertinib will impact clinical practice.